5  Barst RJ,Rubin LJ,Long WA,et al.A comparison of continuous intravenous epoprostenol(prostacyclin)with conventional therapy for primary pulmonary hypertension.N Engl J Med,1996,334:296-302.

　　6  Sitbon O,Humbert M,Simonneau G,et al.Primary pulmonary hypertension:current therapy.Prog Cardiovasc Dis,2002,45:115-128.

　　7  Simonneau G,Barst RJ,Galie N,et al.Continuous subcutaneous infusion of treprostinil,a prostacyclin analogue,in patients with pulmonary arterial hypertension:a double-blind randomized controlled trial.Am J Respir Crit Care Med,2002,165:800-804.

　　8  Gomberg-Maitland M,Tapson VF,Mc Laughlin VV,et al.Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.Am J Respir Crit Care Med，2005,172(12):1586-1589.

　　9  Olschewski H,Simonneau G,Higenbottam T,et al.Inhaled iloprost for severe pulmonary hypertension.N Engl J Med,2002,347(5):322-329.

　　10  Galie N,Manes A,Branzi A.The new clinical trials on pharmacological treatment in pulmonary arterial hypertension.Eur Respir J,2002,20:1037-1049.

　　11  Galie N,Humbert M,Vachiery JL,et al.Effects of beraprost sodium,an oral prostacyclin analogue,in patients with pulmonary arterial hypertension:a randomized,double-blind placebo-controlled trial.J Am Coll Cardiol,2002,39:1496-1502.

　　12  Barst RJ,Mc Goon M,Mclaughlin V,et al.Beraprost therapy for pulmonary arterial hypertension.J Am Coll cardiol,2003,41:2119-2125.

　　13  Cueto E,Lopez-heree J,Sanchez A,et al.Life-threatening efects of dise-tinuing inhaled nitric oxide in ctfildren.Acta Peliatr,1997,86(12):1337-1339.

　　14  lavnie A,Hall JB,Olson D1M,et al.life-threatening efects of di,ontinuing inhaled nitric oxide in sevefe respiratory failure.Am J Respir Crit Care Med,1996,153(6Pt1):1985-1987.

　　15  Atz AM，Adatia I，Wessel DL.1lebound pulnrona～h.｝3mrtension after i lalation of nitric oxide.Ann Thofac Surg,1996,62(6):1759-1761.

　　16  Parks WC,Mecham RP,Crouch EC.Response oflobarvesselsto hypaxie pulmonary hypertension.Am Rev Rospir Dis,1989,140:1455-1457.